

PETITIONER'S EXHIBIT LIST (37 C.F.R. § 42.63(e))

Ex. #	Document
1001	U.S. Patent No. 12,491,184 B2 (the challenged patent)
1002	U.S. Patent No. 12,268,688 B2 (the "'688 patent"; issued April 8, 2025)
1003	U.S. Patent Application Publication No. 2019/0269684 A1 (Samson Clinical Pty Ltd.), published September 5, 2019 ("Sinclair-535"; the U.S. national-phase publication of WO 2019/010535). All Sinclair paragraph citations in this Petition use the paragraph numbering of this U.S. publication.
1004	Reynolds et al., "Investigation of the effect of tablet surface area/volume on drug release from hydroxypropylmethylcellulose controlled-release matrix tablets," <i>Drug Dev. Ind. Pharm.</i> 28(4):457–466 (2002)
1005	Vañó-Galván et al., "Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients," <i>J. Am. Acad. Dermatol.</i> 84(6):1644–51 (2021)
1006	Fleishaker et al., "The pharmacokinetics of 2.5- to 10-mg oral doses of minoxidil in healthy volunteers," <i>J. Clin. Pharmacol.</i> 29:162–167 (1989)
1007	Loniten® (minoxidil tablets) FDA-approved prescribing information (Reference ID 3685475; LAB-0168-0.x, revised January 2015)
1008	Williams, U.S. Patent Application Publication No. 2010/0104639 A1, published April 29, 2010
1009	Biovail, International Publication No. WO 2004/058229
1010	Certified copy of U.S. Provisional Application No. 63/419,155 (filed October 25, 2022), from the WIPO file of PCT/US2023/035920
1011	Certified copy of U.S. Provisional Application No. 63/433,203 (filed December 16, 2022), from the WIPO file of PCT/US2023/035920
1012	Cardinal, U.S. Patent Application Publication No. 2010/0159001 A1, published June 24, 2010
1013	Bokhari et al., "Sublingual minoxidil for the treatment of male and female pattern hair loss: a randomized, double-blind, placebo-controlled, phase 1B clinical trial," <i>J. Eur. Acad. Dermatol. Venereol.</i> 36(1):e62–e66 (2022; published online August 30, 2021)

Ex. #	Document
1014	Panchaprateep et al., "Efficacy and safety of oral minoxidil 5 mg once daily in the treatment of male patients with androgenetic alopecia," <i>Dermatol. Ther. (Heidelb.)</i> 10(6):1345–1357 (2020)
1015	Declaration of Hossein Omidian, Ph.D. (filed herewith)
1016	Reserved
1017	Gottlieb et al., "Pharmacokinetic studies of minoxidil," <i>Clin. Pharmacol. Ther.</i> 13(3):436–441 (1972)
1018	Lowenthal & Affrime, "Pharmacology and Pharmacokinetics of Minoxidil," <i>J. Cardiovasc. Pharmacol.</i> 2(Suppl 2):S93–S106 (1980)
1019	Beach et al., "Low-dose oral minoxidil for treating alopecia: A 3-year North American retrospective case series," <i>J. Am. Acad. Dermatol.</i> 84(3):761–763 (2021)
1020	Reserved
1021	Buhl et al., "Minoxidil Sulfate Is the Active Metabolite that Stimulates Hair Follicles," <i>J. Invest. Dermatol.</i> 95:553–557 (1990)
1022	Reserved
1023	Written Opinion of the International Searching Authority (Form PCT/ISA/237) for PCT/US2023/035920 (USPTO as ISA; February 27, 2024)
1024	Reserved
1025	Reserved
1026	Reserved
1027	Reserved
1028	Reserved
1029	Non-Final Office Action in U.S. Application No. 19/094,703, mailed March 16, 2026
1030	Reserved
1031	Reserved
1032	Reserved
1033	Reserved
1034	Sinha, U.S. Patent Application Publication No. 2024/0374594 A1, published November 14, 2024 (national phase of PCT/US2022/044912, filed September 27, 2022, published as WO 2023/055740)

Ex. #	Document
1035	File history of U.S. Application No. 19/094,716 (Patent Center records, downloaded August 19, 2026), 93 pages: Non-Final Office Action (Apr. 28, 2025), response and terminal disclaimer, information disclosure statements (June 27, Sept. 15, Sept. 18, 2025), PTO-892, and Notices of Allowability (June 18, Aug. 8, Oct. 21, 2025)
1036	Reserved (the three Notices of Allowability appear in Ex. 1035 at 81–89; 37 C.F.R. § 42.6(d))
1037	Reserved
1038	Reserved
1039	Follica/Barman, U.S. Patent Application Publication No. 2019/0381296 A1
1040	Bazzano, International Publication No. WO 83/02558 A1, published August 4, 1983
1041	Samson Clinical, International Publication No. WO 2016/065426 A1, published May 6, 2016
1042	Reserved
1043	Certified copy of U.S. Provisional Application No. 63/250,009 (filed September 29, 2021), from the WIPO file of PCT/US2022/044912
1044	Reserved
1045	Follica/Barman, U.S. Patent No. 11,207,511 B2
1046	Reserved
1047	Reserved
1048	Veradermics, Incorporated, Prospectus (Form 424B4), dated February 3, 2026, filed with the U.S. Securities and Exchange Commission (EDGAR Accession No. 0001628280-26-005505); 338 pages, filed in two parts (Part 1, pp. 1–169; Part 2, pp. 170–338); cited by printed folio — e.g., printed p. 112 is exhibit-stamped p. 166 of 338
1049	Curriculum Vitae of Hossein Omidian, Ph.D.
1050	Veradermics, Inc. press release, "Veradermics' Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 '302' Clinical Trial in Male Pattern Hair Loss" (April 27, 2026), filed as Exhibit 99.1 to Form 8-K (EDGAR Accession No. 0001628280-26-027354)

Ex. #	Document
1051	Veradermics, Inc. press release, "Veradermics' Oral VDPHL01 Delivers Positive Study '207' Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study '306' Readout" (July 15, 2026), filed as Exhibit 99.1 to Form 8-K (EDGAR Accession No. 0001827635-26-000023)
1052	Veradermics, Inc. press release, "Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress" (August 11, 2026), filed as Exhibit 99.1 to Form 8-K (EDGAR Accession No. 0001827635-26-000028)
1053	U.S. Patent Application Publication No. 2020/0108008 A1 (Shanghai Institute of Materia Medica), published April 9, 2020 (incorporated by reference in the '184 patent at cols. 17 and 44)
1054	<i>Teva Pharms. Int'l GmbH v. Eli Lilly & Co.</i> , No. 2024-1094 (Fed. Cir. Apr. 16, 2026) (slip opinion; copy provided per 37 C.F.R. § 42.13(d))
1055	<i>Wyeth LLC v. AstraZeneca Pharms. LP</i> , No. 2024-2325 (Fed. Cir. July 9, 2026) (slip opinion; copy provided per 37 C.F.R. § 42.13(d))
1056	<i>Enviro Tech Chem. Servs., Inc. v. Safe Foods Corp.</i> , No. 2024-2160 (Fed. Cir. May 4, 2026) (slip opinion; copy provided per 37 C.F.R. § 42.13(d))

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. §§ 42.6(e) and 42.205(a), the undersigned certifies that on September 1, 2026, contemporaneously with the filing of this Petition, a complete copy of (1) the Petition for Post-Grant Review of Claims 1–20 of U.S. Patent No. 12,491,184, (2) the Power of Attorney, (3) Petitioner's Exhibit List, and (4) every exhibit and item of supporting evidence filed with the Petition was served by Priority Mail Express® on Patent Owner at the correspondence address of record for U.S. Patent No. 12,491,184, as confirmed in USPTO Patent Center on the date of service:

Procopio, Cory, Hargreaves & Savitch LLP (attorney of record per Ex. 1001, field (74)), 525 B Street, Suite 2200, San Diego, CA 92101

Priority Mail Express® No. 9481 7301 0935 5001 3011 69

and additionally, as an address likely to effect service, on:

Veradermics, Incorporated, 470 James Street, New Haven, Connecticut

06513 (address of principal executive offices per its Form 8-K filed August 11, 2026)

Priority Mail Express® No. 9481 7301 0935 5001 3011 76

/Steven R. Fairchild/

Steven R. Fairchild, Reg. No. 70,800